ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for RSV. Its lead candidate, sisunatovir, is an oral fusion inhibitor being evaluated in two global Phase 2 studies (pediatric and adult stem-cell transplant populations). Sisunatovir has FDA Fast Track designation and showed target exposures with no serious adverse events in Phase 1 and statistically significant reductions in viral load and symptoms in a 2018 Phase 2a challenge study. ReViral also has an in-house N-protein replication inhibitor program in late preclinical development. The company has retained worldwide development and commercialization rights for both programs. ReViral announced a $44 million Series C to support sisunatovir Phase 2 development and to advance the N-protein program into Phase 1. ReViral is an antiviral drug discovery and development company focused on novel treatments for diseases caused by respiratory syncytial virus (RSV). Its lead candidate, RV521, is described as a highly potent, orally bioavailable potential treatment and is expected to enter an international multicentre Phase IIa paediatric trial soon, followed by trials in adult stem cell transplant patients. The company also continues development of a novel series of antiviral inhibitors targeting RSV replication and plans to expand its pipeline. ReViral highlights the high unmet need for RSV therapies, citing global RSV disease burden in children and vulnerable adult populations. Financially, the company completed a US$55 million Series B financing to advance RV521 and its programmes and previously raised US$21 million in a Series A in September 2015. New investors will join the Board of Directors as part of the financing.

Total raised

$99M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2020